- Home
- CLNE vs PRME Comparison
CLNE vs PRME Comparison
Compare CLNE & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLNE | PRME |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.3M | 536.4M |
| IPO Year | 2006 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLNE | PRME |
|---|---|---|
| Price | $2.33 | $3.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.32 | ★ $7.56 |
| AVG Volume (30 Days) | 2.0M | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $4,632,000.00 |
| Revenue This Year | $1.13 | $7.06 |
| Revenue Next Year | $22.65 | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $1.66 | $2.67 |
| 52 Week High | $3.11 | $6.94 |
Technical Indicators
Market Signals| Indicator | CLNE | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 68.75 | 48.30 |
| Support Level | $2.09 | $3.04 |
| Resistance Level | $2.40 | $3.82 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 91.10 | 25.21 |
Price Performance
Historical ComparisonAbout CLNE Clean Energy Fuels Corp.
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.